## MCK: McKesson Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.2% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($796.89)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 8, Bearish: 0)

**1. Assessing McKesson (MCK) Valuation After Fresh Analyst Commentary On Growth And Industry Fundamentals**
- Source: Simply Wall Street | 20260106T213851 | Bullish | Relevance: 100%
- Fresh analyst commentary has highlighted McKesson's 2025 performance, earnings potential, and supportive industry trends, placing the stock back in focus. Trading at $824.92, below an average analyst target of $939.33 and an indicated 41% intrinsic discount, the company appears undervalued with expectations of compounding earnings and a richer mix in the future. However, risks such as drug pricing pressures or vertical integration by manufacturers could impact its thinly-sliced margins.

**2. McKesson Builds Earnings Momentum on Specialty and Automation**
- Source: TradingView — Track All Markets | 20260105T190833 | Bullish | Relevance: 100%
- McKesson delivered a strong fiscal second quarter with consolidated revenues of $103 billion, up 10% year-over-year, and adjusted earnings per diluted share rising 39% to $9.86, leading management to raise full-year guidance. The company’s growth is driven by its North American Pharmaceutical distribution, accelerating specialty volumes, and rising contributions from prescription technology services, particularly within oncology and multispecialty segments. McKesson's long-term strategy focuses on scaling differentiated specialty platforms, leveraging technology and automation for efficiency, and expanding its presence in the biopharma and provider ecosystem.

**3. Who Owns McKesson? Top Shareholders and Recent Insider Trades**
- Source: TIKR.com | 20260105T160840 | Bullish | Relevance: 100%
- McKesson Corporation (NYSE: MCK) is a major healthcare distribution company with a market value of $101.6 billion. Its ownership is primarily anchored by large institutional investors like Vanguard, BlackRock, and State Street, providing long-term stability. While some hedge funds have significantly increased their stakes, insider transactions remain modest and don't signal strong directional views.

**4. Insider Sell: Thomas Rodgers Sells Shares of McKesson Corp (MCK)**
- Source: GuruFocus | 20260106T222815 | Somewhat-Bearish | Relevance: 100%
- Thomas Rodgers, EVP, Chief Strategy & Business Development Officer at McKesson Corp (MCK), sold 276 shares on January 5, 2026. This transaction reduces his total holdings to 2,268 shares, bringing his total sales over the past year to 3,677 shares with no purchases. At the time of the sale, shares were priced at $816.18, and the stock is considered modestly overvalued based on its GF Value of $734.68.

**5. McKesson Corporation (NYSE:MCK) Given Average Recommendation of "Moderate Buy" by Analysts**
- Source: MarketBeat | 20260106T065458 | Bullish | Relevance: 100%
- McKesson Corporation (NYSE: MCK) has received an average "Moderate Buy" recommendation from eighteen analysts, with a mean 12-month price target of $892.86. The company recently surpassed quarterly EPS expectations, reporting $9.86 versus an $8.84 consensus, and its revenue increased by 10.2% year-over-year. Institutional investors hold approximately 85% of the company's stock, and McKesson declared a quarterly dividend of $0.82 per share.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $960 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.28M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.8% (-0.3%)
- Blackrock Inc.: 9.2% (+0.4%)
- State Street Corpora: 4.7% (+0.9%)
- JPMORGAN CHASE & CO: 4.5% (+16.0%)
- Massachusetts Financ: 3.2% (-1.5%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.99 indicates undervaluation relative to growth. Balance sheet: $2.3B free cash flow. Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $102.8B |
| Beta | 0.41 |
| 52W Range | $570.51 - $895.58 |
| Short Interest | 1.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.99 |
| Forward P/E | 18.9 |
| Current P/E | 21.4 |
| YoY Growth | 13.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 weakening modestly (-0.7% over 5 days). Below STRENGTH zone by 3.2pp (needs >3.0% for momentum thesis). MACD histogram positive (1.01), confirming momentum. RSI neutral at 52. OFD pattern: +SUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.25% (CS: 34) | Neutral |
| RSI_14 | 51.6 | Neutral |
| MACD Histogram | 1.01 | Bullish |
| vs SMA20 | 1.010x | Above |
| vs SMA50 | 0.993x | Below |
| vs SMA200 | 1.115x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $826.45
- **Stop Loss:** $796.89 (3.6% risk)
- **Target:** $856.01 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 44
- **Position Value:** $36,363.80
- **Portfolio %:** 36.36%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_ON (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_ON regime with strong participation and low volatility. VIX at 14.75 (6th percentile) with breadth at 63.5% signals healthy risk appetite. Fed dovish expectations and AI/semiconductor momentum are primary drivers, though elevated put/call ratio suggests smart money hedging. Focus on quality growth with awareness of potential complacency.*

### Earnings

**Next:** 2026-02-04 (Est: $9.28)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $9.05 | $9.86 | +8.9% |
| 2025Q2 | $8.15 | $8.26 | +1.4% |
| 2025Q1 | $9.83 | $10.12 | +3.0% |
| 2024Q4 | $7.99 | $8.03 | +0.5% |

---
*RULE-based L3 | 2026-01-07 08:25 | MRS_10*